Evaluation of Side Effects of Mitotane

Rekrutierend

NCT-Nummer:
NCT00568139

Studienbeginn:
Januar 2008

Letztes Update:
26.09.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Carcinoma, Adrenocortical Carcinoma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
University of Wuerzburg

Collaborator:
-

Studienleiter

Martin Fassnacht, MD
Principal Investigator
University of Wuerzburg

Kontakt

Martin Fassnacht, MD
Kontakt:
Phone: +49-931-201-36507
E-Mail: fassnacht_m@medizin.uni-wuerzburg.de» Kontaktdaten anzeigen

Stefanie Hahner, MD
Kontakt:
Phone: +49-931-201-36508
E-Mail: hahner_s@medizin.uni-wuerzburg.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

University Hospital
97080 Wuerzburg
(Bayern)
GermanyRekrutierend» Google-Maps

Studien-Informationen

Brief Summary:

Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many

adverse effects are not well documented. Therefore, we are aiming at collecting data about

adverse effects in patients treated with mitotane

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Adrenocortical carcinoma

- Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or

advanced disease)

Studien-Rationale

Primary outcome:

1. Documentation of adverse effects (Time Frame - from starting mitotane until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years) or start of additional other medical therapies):
Adverse effects will be documented using the NCI CTC AE v5.5

Quelle: ClinicalTrials.gov